



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, MD¹, Jennifer R. Brown, MD PhD², Paolo Ghia, MD PhD³, Lindsey E. Roeker, MD⁴, Krish Patel, MD⁵, Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD⁶, Talha Munir, MBBS, MRCP, FRCPath, PhD⁷, Ewa Lech-Maranda, MD PhD⁸, Nicole Lamanna, MD⁹, Constantine S. Tam, MBBS, MD FRACP, FRCPA¹⁰, John F. Seymour, MBBS, PhD FRACP¹¹, Benoit Tessoulin¹², Nirav N. Shah, MD¹³, Chaitra S Ujjani, MD¹⁴, Bita Fakhri, MD MPH¹⁵, Catherine C. Coombs, MD¹⁶, Ian W. Flinn, MD PhD¹⁷, Manish Patel, MD¹⁸, Sunita D. Nasta, MD¹⁹, Jonathon B. Cohen, MDMS²⁰, Alvaro J. Alencar, MD²¹, Chan Y. Cheah, MD DMSc²², Shuo Ma, MD PhD²³, Joanna M. Rhodes, MD MSCE²⁴, Deepa Jagadeesh, MD²⁵, Pier Luigi Zinzani, MD PhD²⁶, Anders Osterborg, MD PhD²⁷, Koji Izutsu, MD PhD²⁸, Donald E. Tsai, MD PhD²⁹, Paolo Abada, MD²⁹, Minna Balbas, PhD²⁹, Jian Li, MS²⁹, Amy S. Ruppert, PhD³⁰, Wojciech Jurczak, MD PhD³¹, William G. Wierda, MD PhD³²

¹ The Ohio State University Comprehensive Cancer Center, Columbus, OH

² Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

³ Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

⁴ Memorial Sloan Kettering Cancer Center, New York, NY

⁵ Swedish Cancer Institute, Seattle, WA

⁶ Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

⁷ Department of Haematology, St. James's University Hospital, Leeds, United Kingdom

⁸ Institute of Hematology and Transfusion Medicine, Warsaw, Poland

⁹ Herbert Irving Comprehensive Cancer Center, Columbia University, New York

¹⁰ Alfred Health and Monash University, Melbourne, Australia

¹¹ Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia

¹² Hematology Department, University Hospital, Nantes, France

¹³ Medical College of Wisconsin, Milwaukee, WI

¹⁴ Fred Hutchinson Cancer Research Center, Seattle, WA

¹⁵ Stanford University School of Medicine, Stanford, CA

¹⁶ University of California Irvine, Irvine, CA

¹⁷ Sarah Cannon Research Institute, Nashville, TN

¹⁸ Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL

¹⁹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

²⁰ Winship Cancer Institute, Emory University, Atlanta, GA

²¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

²² Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

²³ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

²⁴ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

²⁵ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

²⁶ Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy

²⁷ Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

²⁸ National Cancer Center Hospital, Tokyo, Japan

²⁹ Loxo@Lilly, Indianapolis, IN

³⁰ Eli Lilly and Company, Indianapolis, IN

³¹ Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

³² MD Anderson Cancer Center, Houston, TX

Background: The treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has benefited from covalent (c) Bruton tyrosine kinase inhibitors (BTKi), however, therapy can fail due to progression or intolerance. Sequential treatment with B-cell lymphoma 2 protein inhibitor (BCL2i) venetoclax, either as monotherapy or combined with an anti-CD20 monoclonal antibody, has been the primary treatment option for CLL/SLL patients (pts) whose disease has progressed on cBTKi. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that demonstrated promising efficacy in patients with relapsed or refractory CLL/SLL (Mato et al, NEJM, 2023). Here, we report on the efficacy of pirtobrutinib treatment in CLL/SLL in the post-cBTKi setting, including subgroups with or without prior BCL2i, using data from the BRUIN study (NCT03740529) with more than 2 years follow-up.

Methods: Pts with previously treated CLL/SLL were eligible for treatment with pirtobrutinib in the multicenter Phase 1/2 BRUIN study. Key endpoints included ORR (including partial response with lymphocytosis; PR-L) as assessed by an independent review committee per 2018 iwCLL response criteria, DoR, PFS, OS, and safety. A data cut of 05MAY2023 was utilized.

Results: In total, 282 pts with CLL/SLL who received prior cBTKi were included in this analysis. Median age was 69 years (range, 36-88), 68% were male, and median number of prior therapies was 4 (range, 1-11). Of 282 pts, 154 (55%) had not received prior-BCL2i therapy (Naïve; BCL2i-N) and 128 (45%) had (Exposed; BCL2i-E). BCL2i-N pts were exposed to fewer prior therapies than BCL2i-E pts (median prior therapies 3 and 5, respectively), including anti-CD20 antibody (83% and 97%), chemotherapy (74% and 89%), PI3K inhibitor (11% and 42%), CAR-T cell therapy (1% and 12%), and hematopoietic cell transplantation (1% and 6%). The ORR for all post-cBTKi pts was 72% (95% CI, 66.4-77.1), and ORR including PR-L was 82% (95% CI, 76.5-85.9). Post-cBTKi pts included a subgroup of 19 pts with one prior line of cBTKi-containing therapy and second line therapy of pirtobrutinib, who had ORR including PR-L of 89.5% (CI 95%, 66.9-98.7). The ORR including PR-L was 83.1% (95% CI, 76.2-88.7) for BCL2i-N pts, and 79.7% (95% CI, 71.7-86.3) for BCL2i-E pts. Median DoR was 18.4 months (95% CI, 15.3-20.4) for all cBTKi pre-treated pts, 24.9 months (95% CI, 18.4-32.0) for BCL2i-N, and 14.8 months (95% CI, 12.0-17.4) for BCL2i-E. With a median follow up of 27.5 months, the median PFS was 19.4 months (95% CI, 16.6-22.1) among all cBTKi pre-treated pts, 23.0 months (95% CI, 19.6-28.4) for BCL2i-N, and 15.9 months (95% CI, 13.6-17.5) for BCL2i-E (Figure). With a median follow up of 29.3 months, the median OS was not estimable for all cBTKi pre-treated pts, BCL2i-N, and BCL2i-E; the 24-month OS rates were 73.2% (95% CI, 67.4-78.2), 83.1% (95% CI, 75.9-88.2), 60.6% (50.9-68.9), respectively.

In the CLL/SLL cohort (N=282), the most frequent treatment-emergent adverse events (TEAE), regardless of attribution, were fatigue (36.9%), diarrhea (28.4%), cough (27.3%) and contusion (26.2%). The most frequent Grade ≥ 3 TEAE was neutropenia/neutrophil count decreased (28.4%). Grade ≥ 3 TEAEs of hypertension (4.3%) and atrial fibrillation/flutter (1.8%) were infrequent. The AE profile of BCL2i-N and BCL2i-E pts was overall similar. Though Grade ≥ 3 neutropenia/neutrophil count decreased was higher in BCL2i-E pts (36.7% and 21.4%), this may have been attributed to the higher frequency of baseline neutropenia in BCL2i-E pts (27.3% and 11.0%). In total, 7 (2.5%; 4 BCL2i-N, 3 BCL2i-E) pts had treatment-related AE leading to pirtobrutinib discontinuation.

Conclusion: Pirtobrutinib continues to demonstrate promising and durable efficacy in pts with post-cBTKi heavily pretreated CLL/SLL. ORR was high regardless of prior BCL2i status. Longer PFS was observed in BCL2i-N pts than BCL2i-E pts, likely due to the more heavily pretreated status of the BCL2i-E population which can be associated with poorer prognosis. Pirtobrutinib was well-tolerated with low-rates of discontinuation due to drug-related toxicity among both BTKi-N and BTKi-E pts. These results suggest that continuation of BTK pathway inhibition following a cBTKi may be an important sequencing approach to consider in the treatment of CLL/SLL.

Disclosures Woyach: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.; Other: Contracted Research; AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie: Other: Advisory Committee and Consulting Agreements. **Brown:** SecuraBio: Research Funding; MEI Pharma: Research Funding; Hutchmed: Consultancy; Grifols Worldwide Operations: Consultancy; Pfizer: Consultancy; Kite: Consultancy; Numab Therapeutics: Consultancy; Merck: Consultancy; Loxo@Lilly: Consultancy, Research Funding; iOnctura: Consultancy, Research Funding; TG Therapeutics: Research Funding; Alloplex Biotherapeutics: Consultancy; Beigene: Consultancy, Research Funding; Genentech/Roche: Consultancy; Pharmacyclics: Consultancy; Gilead: Research Funding; Acerta/Astra-Zeneca: Consultancy; AbbVie: Consultancy. **Ghia:** Roche: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Lilly/Loxo Oncology: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. **Roeker:** Loxo Oncology: Consultancy, Other: travel support, Research Funding; Medscape: Other: CME speaker; Adaptive Biotechnologies: Research Funding; Curio: Other: CME speaker; DAVA: Other: CME speaker; PeerView: Other: CME speaker; Aptose Biosciences: Research Funding; Genentech: Research Funding; Janssen: Consultancy; Ascentage: Consultancy; AstraZeneca: Consultancy, Research Funding; Beigene: Consultancy; Pharmacyclics: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy; Dren Bio: Research Funding; Qilu Puget Sound Biotherapeutics: Research Funding; Abbott Laboratories: Current equity holder in publicly-traded company; AbbVie: Consultancy, Research Funding. **Patel:** Abbvie: Consultancy; Fate Therapeutics: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Curis, Inc: Research Funding; Xencor: Consultancy, Research Funding; Morphosys: Consultancy; Merck: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Loxo Oncology: Consultancy, Research Funding; Kite: Consultancy, Research Funding, Speak-

ers Bureau; *Genentech/Roche*: Consultancy, Research Funding; *Epizyme*: Consultancy, Research Funding; *CRISPR Therapeutics*: Research Funding; *Caribou Biosciences*: Consultancy; *Bristol Myers Squibb*: Consultancy, Research Funding, Speakers Bureau; *BeiGene*: Consultancy; *ADC Therapeutics*: Consultancy; *Nurix*: Research Funding; *Pharmacyclics/Janssen*: Consultancy, Research Funding; *Sunesis Pharmaceuticals*: Research Funding; *TG Therapeutics*: Consultancy, Speakers Bureau; *Trillium Therapeutics/Pfizer*: Consultancy, Research Funding; *Adaptive Biotechnologies*: Research Funding. **Eyre**: *Loxo Lilly*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *KITE*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Autolus*: Consultancy; *Janssen*: Consultancy, Honoraria, Speakers Bureau; *Gilead*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Eli Lilly and Company*: Consultancy, Honoraria, Speakers Bureau; *PeerView*: Speakers Bureau; *Medscape*: Speakers Bureau; *Secura Bio*: Membership on an entity's Board of Directors or advisory committees; *Loxo Oncology*: Consultancy, Honoraria, Other, Speakers Bureau; *Incyte*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Abbvie*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Beigene*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *AstraZeneca*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *Roche*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Munir**: *BeiGene*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Alexion*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Sobi*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Roche*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *AstraZeneca*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Janssen*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *Abbvie*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Lamanna**: *Abbvie*: Consultancy, Research Funding; *Octapharma*: Research Funding; *Janssen*: Consultancy; *Oncternal*: Research Funding; *MingSight*: Research Funding; *Eli Lilly/Loxo*: Research Funding; *Pharmacyclics*: Consultancy; *Adaptive Biotechnologies*: Consultancy; *TG Therapeutics*: Research Funding; *Genentech*: Consultancy, Research Funding; *BeiGene*: Consultancy, Research Funding; *AstraZeneca*: Consultancy, Research Funding. **Tam**: *Janssen*: Honoraria, Research Funding; *AbbVie*: Honoraria, Research Funding; *Beigene*: Honoraria, Research Funding; *LOXO*: Honoraria; *Novartis*: Honoraria; *Roche*: Honoraria. **Seymour**: *F. Hoffmann-La Roche Ltd*: Research Funding; *AstraZeneca*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Hoffmann-La Roche*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Janssen*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *AbbVie*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *TG Therapeutics*: Consultancy; *Gilead*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Beigene*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *BMS*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Genor Bio*: Membership on an entity's Board of Directors or advisory committees. **Tessoulin**: *Gilead*: Honoraria; *Abbvie*: Honoraria; *Incyte*: Honoraria; *Kite*: Honoraria. **Shah**: *Epizyme*: Consultancy; *Janssen*: Consultancy; *Novartis*: Consultancy; *TG therapeutic*: Consultancy; *Umoja*: Consultancy; *LOXO-Lilly*: Consultancy, Other: Travel support; *Tundra Therapeutics*: Current holder of stock options in a privately-held company; *BMS/Juno*: Consultancy; *Seattle Genetics*: Consultancy; *Gilead/Kite*: Consultancy; *Incyte*: Consultancy; *Abbvie*: Consultancy; *Lilly Oncology*: Consultancy, Research Funding; *Miltenyi Biotec*: Consultancy, Other: Travel support, Research Funding. **Ujjani**: *Kite, a Gilead Company*: Consultancy, Other: Travel expenses, Research Funding; *Lilly*: Consultancy, Honoraria, Research Funding; *Janssen*: Consultancy, Honoraria; *Pharmacyclics*: Consultancy, Honoraria, Research Funding; *Genentech*: Consultancy, Honoraria; *Beigene*: Consultancy, Honoraria; *Abbvie*: Consultancy, Honoraria, Research Funding; *Atara*: Consultancy; *Epizyme*: Consultancy; *Astrazeneca*: Consultancy, Honoraria, Research Funding; *PCYC*: Research Funding. **Fakhri**: *BeiGene*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *AstraZeneca*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *ADC Therapeutics*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *Abbvie*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *BMS/Juno*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *Genetech*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Genmab/Abbvie*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *LOXO/Lilly*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Pharmacyclics*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. **Coombs**: *AbbVie*, *Genentech*, *Beigene*, *AstraZeneca*, *Lilly*, *Octapharma*: Consultancy. **Flinn**: *Genmab*: Consultancy; *BeiGene*: Consultancy; *Genentech*: Consultancy; *Secura Bio*: Consultancy; *Hutchinson MediPharma*: Consultancy; *Kite*: Consultancy; *Innocyte Pharma*: Consultancy; *AbbVie*: Consultancy; *Novartis*: Consultancy; *Myeloid Therapeutics*: Consultancy; *Servier Pharma*: Consultancy; *Century Therapeutics*: Consultancy; *TG Therapeutics*: Consultancy; *Vincerx Pharma*: Consultancy. **Patel**: *ION Pharmaceuticals*: Other: Leadership; *Olema Pharmaceuticals*: Membership on an entity's Board of Directors or advisory committees; *Janssen Oncology*: Honoraria. **Nasta**: *ADC Therapeutics*: Honoraria; *Loxo/Lilly*: Research Funding; *Millennium Takeda*: Research Funding; *Ono Pharmaceutical*: Research Funding; *Accrotech*: Honoraria; *Raphael*: Research Funding; *Pharmacyclics*: Research Funding; *Genentech/Roche*: Research Funding; *Merck-Data Safety Monitoring Committee*: Membership on an entity's Board of Directors or advisory committees. **Cohen**: *BMS/Celgene*: Research Fund-

ing; *Novartis*: Research Funding; *Genentech*: Research Funding; *BioInvent*: Research Funding; *Lam Therapeutics*: Research Funding; *Takeda*: Research Funding; *ADCT*: Consultancy; *AstraZeneca*: Consultancy, Research Funding; *Abbvie*: Consultancy; *Janssen*: Consultancy; *BeiGene*: Consultancy; *Loxo/Lilly*: Consultancy, Research Funding. **Alencar**: *Genentech*: Membership on an entity's Board of Directors or advisory committees; *Dr Reddy*: Honoraria; *Lilly*: Membership on an entity's Board of Directors or advisory committees; *Amgen*: Membership on an entity's Board of Directors or advisory committees; *TG Therapeutics*: Membership on an entity's Board of Directors or advisory committees; *Incyte*: Membership on an entity's Board of Directors or advisory committees; *Beigene*: Membership on an entity's Board of Directors or advisory committees; *Janssen*: Membership on an entity's Board of Directors or advisory committees; *Epizyme*: Membership on an entity's Board of Directors or advisory committees; *SeaGen*: Membership on an entity's Board of Directors or advisory committees. **Cheah**: *TG therapeutics*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Gilead*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *AbbVie*: Research Funding; *Eli Lilly and Company*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *AstraZeneca*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *MSD*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Novartis*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *BMS*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *BeiGene*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Ascentage Pharma*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Roche*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Research Funding; *Janssen*: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Menarini*: Consultancy, Honoraria; *Genmab*: Consultancy, Honoraria; *Daizai*: Consultancy, Honoraria. **Ma**: *Juno/BMS*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *AstraZeneca*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *Eli Lilly and Company/Loxo Oncology*: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; *Genentech*: Consultancy; *Abbvie*: Consultancy, Research Funding; *Janssen Pharmaceuticals*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; *BeiGene*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Rhodes**: *Acerta*: Research Funding; *Oncternal Pharmaceuticals*: Research Funding; *Loxo Oncology*: Research Funding; *SeaGen*: Consultancy; *GenMab*: Consultancy; *Epizyme*: Consultancy; *ADCT*: Consultancy; *Morphosys*: Consultancy; *AstraZeneca*: Consultancy; *Beigene*: Consultancy; *Pharmacyclics*: Consultancy, Research Funding; *Janssen*: Consultancy; *Genentech*: Consultancy; *AbbVie*: Consultancy, Research Funding; *Velosbio*: Research Funding; *Verastem*: Consultancy; *PCYC*: Consultancy. **Jagadeesh**: *LOXO Pharmaceuticals*: Research Funding; *ATARA Biotherapeutics*: Research Funding; *Debio Pharma*: Research Funding; *Regeneron Pharmaceuticals*: Research Funding; *Affimed*: Membership on an entity's Board of Directors or advisory committees; *Trillium Pharmaceuticals*: Research Funding; *Seagen*: Research Funding; *MEI Pharma*: Research Funding; *AstraZeneca*: Research Funding; *Daiichi Sankyo*: Membership on an entity's Board of Directors or advisory committees. **Zinzani**: *ASTRAZENECA*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *SANDOZ*: Membership on an entity's Board of Directors or advisory committees; *CELLTRION*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *MSD*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *SECURA BIO*: Membership on an entity's Board of Directors or advisory committees; *GILEAD*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *JANSSEN-CILAG*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *BMS*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *TAKEDA*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *ROCHE*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *SERVIER*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *KYOWA KIRIN*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *EUSAPHARMA*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *NOVARTIS*: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *ADC THERAPEUTICS*: Membership on an entity's Board of Directors or advisory committees; *INCYTE*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *BEIGENE*: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Izutsu**: *Beigene*: Research Funding; *Takeda*: Consultancy, Honoraria; *Nippon Shinyaku*: Consultancy; *Novartis*: Honoraria, Research Funding; *Bristol Myers Squibb*: Honoraria, Research Funding; *Mitsubishi Tanabe Pharma*: Consultancy; *Astellas Amgen*: Research Funding; *Incyte*: Research Funding; *Loxo Oncology*: Research Funding; *Eli Lilly*: Honoraria; *SymBio Pharmaceuticals*: Honoraria; *Regeneron*: Research Funding; *Eisai*: Consultancy, Honoraria, Research Funding; *Daiichi Sankyo*: Honoraria, Research Funding; *Genmab*: Consultancy, Honoraria, Research Funding; *AstraZeneca*: Consultancy, Honoraria, Research Funding; *Meiji Seika*: Honoraria; *Yakult*: Research Funding; *Janssen*: Honoraria; *Ono Pharmaceuticals*: Consultancy, Honoraria; *Nihon Kayaku*: Honoraria; *MSD*: Honoraria, Research Funding; *Pfizer*: Honoraria, Research Funding; *Chugai Pharma*: Honoraria, Research Funding; *Kyowa Kirin*: Honoraria, Research Funding; *Zenyaku Kogyo*: Consultancy; *Otsuka*: Consultancy, Research Funding; *Abbvie*: Consultancy, Honoraria, Research Funding. **Tsai**: *Loxo@Lilly*: Current Employment; *Eli Lilly and Company*: Current equity holder in publicly-traded company. **Abada**: *Eli Lilly and Company*: Current Employment, Current equity holder in publicly-traded company. **Balbas**: *Eli Lilly and Company*: Current Employment, Current equity holder in publicly-traded company. **Li**: *Eli Lilly and Company*: Current equity holder in publicly-traded company. **Ruppert**: *Telios Pharma*: Consultancy; *Eli Lilly and Company*: Current Employment, Current equity holder in publicly-traded

company. **Jurczak:** SOBI: Research Funding; AbbVie: Consultancy; BeiGene: Consultancy; AstraZeneca: Research Funding; AbbVie: Research Funding; Roche: Research Funding; Eli Lilly: Consultancy; BeiGene: Research Funding; Pfizer: Consultancy; AstraZeneca: Consultancy; Bayer: Research Funding; Takeda: Research Funding; Roche: Consultancy; SOBI: Consultancy; Takeda: Consultancy; Celgene: Research Funding; Janssen: Research Funding; Eli Lilly: Research Funding; Merck: Research Funding; Pfizer: Research Funding. **Wierda:** Genentech: Research Funding; Juno Therapeutics: Research Funding; Sunesis: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; Nurix Therapeutics: Research Funding; Pharmacyclics LLC: Research Funding; Gilead Sciences: Research Funding; AbbVie: Consultancy, Research Funding; Oncternal Therapeutics, Inc.: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Cyclacel: Consultancy, Research Funding; Miragen: Research Funding; KITE Pharma: Research Funding; GlaxoSmithKline: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Janssens Biotech: Research Funding; Janssens Biotech Inc: Research Funding; Numab Therapeutics: Research Funding; Accutar Biotechnology: Research Funding; NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; GSK/Novartis: Research Funding.

OffLabel Disclosure: Pirtobrutinib is approved in the USA for treatment of relapsed or refractory MCL after at least 2 lines of systemic therapy, including prior BTKi.




Figure 1

<https://doi.org/10.1182/blood-2023-185852>